Dénomination Commune Française
Dénomination Commune Française (DCF) is a system used in France for the generic naming of pharmaceutical substances. It is managed by the Agence nationale de sécurité du médicament et des produits de santé (ANSM), the French National Agency for Medicines and Health Products Safety. The DCF is equivalent to the International Nonproprietary Name (INN) system used internationally.
Overview[edit | edit source]
The DCF system was established to provide a standardized nomenclature for pharmaceutical substances. This is to ensure that healthcare professionals and patients can accurately identify and communicate about specific drugs, regardless of brand name. The DCF is used in all official documents and databases related to medicines in France.
Each DCF name is unique and is assigned to a specific active ingredient. The names are chosen to be clear, concise, and easy to remember, and they often reflect the chemical structure or pharmacological properties of the substance.
Process of DCF Naming[edit | edit source]
The process of assigning a DCF name to a new pharmaceutical substance begins when a pharmaceutical company submits an application to the ANSM. The application must include detailed information about the substance, including its chemical structure, pharmacological properties, and proposed uses.
The ANSM reviews the application and, if it is approved, assigns a DCF name to the substance. The name is then published in the Journal officiel de la République française, the official journal of the French Republic.
Comparison with Other Naming Systems[edit | edit source]
While the DCF system is specific to France, it is similar to other pharmaceutical naming systems used around the world. The most widely used system is the INN, which is managed by the World Health Organization (WHO). Like the DCF, the INN system assigns unique names to pharmaceutical substances, but it is used internationally rather than in a specific country.
See Also[edit | edit source]
- International Nonproprietary Name
- United States Adopted Name
- British Approved Name
- Japanese Accepted Name
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
